10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
A report has predicted a significant growth in the Pompe disease market size due to growing general physician awareness and improvement in diagnosis models, according to GlobalData, a leading data and analytics company. 14 December 2018
Swiss cell and gene therapy specialist Axovant Sciences has licensed exclusive worldwide rights for the development and commercialization of two novel gene therapy programs to address GM1 gangliosidosis and GM2 gangliosidosis (also known as Tay-Sachs and Sandhoff diseases) from the University of Massachusetts (UMass) Medical School. 14 December 2018
AstraZeneca and its global biologics research and development arm MedImmune, have presented overall survival (OS) and progression-free survival (PFS) data from the Phase III MYSTIC trial at the European Society for Medical Oncology (ESMO) Immuno-Oncology 2018 Congress in Geneva, Switzerland. 14 December 2018
Shares in Applied Genetic Technologies plummeted almost 50% on Thursday, after the firm revealed biotech major Biogen was tearing up a 2015 deal that could have been worth a billion dollars. 14 December 2018
Having taken an exclusive option to acquire US biotech firm Potenza Therapeutics back in 2015, as part of a research collaboration, Japanese pharma major Astellas Pharma yesterday closed the transaction. 14 December 2018
CTI BioPharma saw its shares fall 7.77% to $1.36 yesterday, after it announced a restructuring plan to improve efficiencies and reduce costs within the organization. 14 December 2018
UK and USA-based clinical-stage biotech Orchard Therapeutics has signed a long-term lease agreement to build-out a gene therapy manufacturing facility in Fremont, California. 13 December 2018
GenSight Biologics has seen its share price nearly triple since late October as expectations rise on its lead product candidate, and the company kept the good data coming with a presentation on Wednesday. 13 December 2018
Johnson & Johnson has announced positive data from the Phase III ECLIPSE study showing that Tremfya (guselkumab) was superior to Novartis’ Cosentyx (secukinumab) in moderate to severe plaque psoriasis. 13 December 2018
US pharma giant Merck & Co and Instituto Butantan, Sao Paulo, Brazil, a non-profit producer of immunobiologic products for Brazil have entered into a collaboration agreement to develop vaccines to protect against dengue virus disease, the mosquito-borne infection. 13 December 2018
The European Commission (EC) has approved Xolair (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment. 13 December 2018
Japanese biotech firm Sosei Group today announced that its board of directors, at a meeting held on December 11, 2018, approved a change in its president and chief executive (CEO). 12 December 2018
UK biotech firm Circassia Pharmaceuticals today announced that it is exercising its option to acquire the full US commercial rights to Tudorza (aclidinium) from AstraZeneca. 11 December 2018
Astellas Pharma today announced that Xospata (gilteritinib) is now available for prescription in the USA for the treatment of adult patients who have relapsed or refractory (resistant to treatment) acute myeloid leukemia (AML) with a FLT3 mutation as detected by a Food and Drug Administration-approved test. 11 December 2018
Australia has become the first country anywhere to grant regulatory approval to a cancer drug originally found in a marine microorganism. 11 December 2018
USA-based HiFiBiO Therapeutics has today announced the formation of Victa Biotherapeutics, a joint venture with Vikas Sukhatme, Robert W Woodruff Professor of Medicine and Dean of Emory University School of Medicine. 11 December 2018
Chinese biotech firm HitGen has entered into a drug discovery research collaboration with Japanese drugmaker Mitsubishi Tanabe Pharma to identify novel small molecule leads for targets of interest. 11 December 2018
A trial of a treatment for REM sleep behavior disorder failed to meet its main goal, said Switzerland-based biotech firm Axovant Sciences. 11 December 2018
New research predicts that the atopic dermatitis market will grow from $6.4 billion in 2017 to $18.3 billion in 2027 across the seven major markets (7MM = USA, France, Germany, Italy, Spain, the UK, and Japan), expanding at a compound annual growth rate (CAGR) of 11.1%. 11 December 2018